Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Undersøgelse af Palifosfamid-tris i kombination med carboplatin og etoposid i kemoterapi-naive patienter med småcellet lungekræft i omfattende stadier (MATISSE-undersøgelsen)

29. september 2026 opdateret af: Alaunos Therapeutics

En multicenter, open-label, adaptiv, randomiseret undersøgelse af Palifosfamide-tris, en ny DNA-krydsbinder, i kombination med carboplatin og etoposid (PaCE) kemoterapi versus carboplatin og etoposid (CE) alene i kemoterapi-naive patienter med små, omfattende stadier Celle lungekræft. MATISSE-undersøgelsen

This is a multinational, multicenter, randomized controlled, open-label, adaptive study to evaluate the efficacy of palifosfamide-tris, carboplatin and etoposide (PaCE) chemotherapy in chemotherapy-naive subjects with extensive-stage small cell lung cancer (SCLC). Eligible subjects will be stratified according to age, gender, and Eastern Cooperative Oncology Group (ECOG) performance status, and randomized in a 1:1 ratio to receive either PaCE or carboplatin and etoposide (CE) chemotherapy.

The study design uses an adaptive group sequential approach with sample size re-estimation at the interim analysis.

Secondary efficacy endpoints include objective response rate (ORR), progression-free survival (PFS), duration of response and changes in quality of life (QOL) and disease-related symptoms. Tumor-related endpoints will be assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 guidelines.

The safety of study treatments will be assessed by the frequency and severity of adverse events as determined by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03. To provide an initial confirmation of safety, an early interim analysis of safety data only will be performed.

An independent Data Monitoring Committee (DMC) will be convened to assess the safety and efficacy of the study interventions and to monitor the overall conduct of the clinical trial.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

188

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • New South Wales
      • Wollongong, New South Wales, Australien, 2500
        • Southern Medical Day Oncology Care Centre
    • Manitoba
      • Winnipeg, Manitoba, Canada, R3E 0V9
        • CancerCare Manitoba
    • Ontario
      • Oshawa, Ontario, Canada, L1G 2B9
        • R. S. McLaughlin Durham Regional Cancer Center at Lakeridge Health Oshawa
    • Quebec
      • Sainte-Foy, Quebec, Canada, G1V 4G5
        • Hôpital Laval
    • England
      • Manchester, England, Det Forenede Kongerige, M23 9LT
        • Wythenshawe Hospital
    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35205
        • Birmingham Hematology and Oncology Associates, LLC
    • California
      • Los Angeles, California, Forenede Stater, 90033
        • University of Southern California
      • Santa Rosa, California, Forenede Stater, 95403
        • Redwood Regional Oncology Group
    • Delaware
      • Newark, Delaware, Forenede Stater, 19713
        • Christiana Care Health Services
    • Florida
      • Jacksonville, Florida, Forenede Stater, 32207
        • Baptist Cancer Institute
      • Port Saint Lucie, Florida, Forenede Stater, 34952
        • Hematology Oncology Associates of the Treasure Coast
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30318
        • Peachtree Hematology Oncology Consultants
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60612
        • Rush University Medical Center
      • Galesburg, Illinois, Forenede Stater, 61401
        • Medical and Surgical Specialists, LLC
      • Niles, Illinois, Forenede Stater, 60714-5905
        • Illinois Cancer Specialists
    • Indiana
      • Fishers, Indiana, Forenede Stater, 46037
        • Central Indiana Cancer Centers
      • Goshen, Indiana, Forenede Stater, 46526
        • Goshen Center for Cancer Care
      • Indianapolis, Indiana, Forenede Stater, 46202
        • Indiana University
      • Lafayette, Indiana, Forenede Stater, 47905
        • Horizon Oncology Center
      • Muncie, Indiana, Forenede Stater, 47303
        • Indiana University Health Ball Memorial Hospital
    • Kansas
      • Overland Park, Kansas, Forenede Stater, 66210
        • University of Kansas Hospital
    • Kentucky
      • Lexington, Kentucky, Forenede Stater, 40503
        • Central Baptist Hospital
    • Louisiana
      • Baton Rouge, Louisiana, Forenede Stater, 70809
        • Medical Oncology, LLC
    • Maryland
      • Frederick, Maryland, Forenede Stater, 21701
        • Frederick Memorial Hospital Regional Cancer Therapy Center
    • Michigan
      • Wyoming, Michigan, Forenede Stater, 49519
        • Metro Health Cancer Center
    • Minnesota
      • Duluth, Minnesota, Forenede Stater, 55805
        • Saint Mary's Medical Center
      • Minneapolis, Minnesota, Forenede Stater, 55407
        • Virginia Piper Cancer Institute
    • New Jersey
      • Hackensack, New Jersey, Forenede Stater, 07601
        • John Theurer Cancer Center at Hackensack University Medical Center
      • Morristown, New Jersey, Forenede Stater, 07962
        • Hematology Oncology Associates of Northern New Jersey, PA, Carol G. Simon Cancer Center
    • New Mexico
      • Albuquerque, New Mexico, Forenede Stater, 87106
        • University of New Mexico Cancer Center
    • New York
      • Albany, New York, Forenede Stater, 12110-2188
        • New York Oncology Hematology, PC
      • The Bronx, New York, Forenede Stater, 10461
        • Montefiore Medical Center
    • Ohio
      • Cincinnati, Ohio, Forenede Stater, 45219
        • The Christ Hospital
      • Dayton, Ohio, Forenede Stater, 45429
        • Dayton Cancer Center, Medical Oncology Hematology Associates
    • Pennsylvania
      • Kingston, Pennsylvania, Forenede Stater, 18704
        • Medical Oncology Associates Of Wyoming Valley, PC
    • South Carolina
      • Charleston, South Carolina, Forenede Stater, 29403
        • Charleston Hematology Oncology Associates, PA
    • Texas
      • Dallas, Texas, Forenede Stater, 75230-6899
        • Texas Oncology-Medical City Dallas
      • Dallas, Texas, Forenede Stater, 75246
        • Texas Oncology- Baylor, Charles A. Sammons Cancer Center
      • Galveston, Texas, Forenede Stater, 77555-0565
        • University of Texas Medical Branch at Galveston
      • Houston, Texas, Forenede Stater, 77024
        • Oncology Consultants, PA
      • Wichita Falls, Texas, Forenede Stater, 76310-1610
        • Texas Oncology, PA
    • Vermont
      • Burlington, Vermont, Forenede Stater, 05405
        • Fletcher Allen Health Care
    • Virginia
      • Fairfax, Virginia, Forenede Stater, 22031
        • Fairfax Northern Virginia Hematology-Oncology, PC
    • Washington
      • Seattle, Washington, Forenede Stater, 98104
        • Swedish Medical Center
    • Wisconsin
      • Madison, Wisconsin, Forenede Stater, 53705
        • Wisconsin Institutes for Medical Research
      • Strasbourg, Frankrig, 67085
        • Centre Paul Strauss
    • Auvergne-Rhône-Alpes
      • Pierre Bénité, Auvergne-Rhône-Alpes, Frankrig, 69495
        • Centre Hospitalier Lyon Sud
    • Basse-normandie
      • Caen, Basse-normandie, Frankrig, 14076
        • Centre François Baclesse
    • Brittany Region
      • Brest, Brittany Region, Frankrig, 29200
        • Centre Hospitalier Universitaire -Hôpital Morvan
    • Centre-Val de Loire
      • Tours, Centre-Val de Loire, Frankrig, 97044
        • Centre Hospitalier Universitaire, Hopital Bretonneau
    • Limousin, Lorraine
      • Limoges, Limousin, Lorraine, Frankrig, 87042
        • Hôpital du Cluzeau
    • Pays de la Loire Region
      • Saint-Herblain, Pays de la Loire Region, Frankrig, 44805
        • Institut de Cancérologie de l'Ouest - René Gauducheau
    • Provence-Alpes-Côte d'Azur Region
      • Marseille, Provence-Alpes-Côte d'Azur Region, Frankrig, 13008
        • Hôpital Saint Joseph
      • Haifa, Israel
        • Rambam Medical Center
      • Jerusalem, Israel, 91120
        • Hadassah Medical Organization, Ein Kerem
      • Kfar Saba, Israel
        • Meir Hospital Sapir Medical Center
      • Nahariya, Israel, 22100
        • Western Gallilee Medical Center
      • Petah Tikva, Israel, 49100
        • Rabin Medical Center Beilinson Campus
      • Genova, Italien
        • Istituto Nazionale per la Ricerca sul Cancro
      • Milan, Italien, 20162
        • Azienda Ospedaliera Ospedale Niguarda Ca' Granda
      • Trento, Italien, 38100
        • Presidio Ospedaliero S. Chiara
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Polen
        • Centrum Onkologii - Instytut im. M. Sklodowskiej-Curie w Warszawie
    • Pomeranian Voivodeship
      • Gdansk, Pomeranian Voivodeship, Polen
        • Uniwersyteckie Centrum Kliniczne
      • Gdansk, Pomeranian Voivodeship, Polen
        • Wojewódzkie Centrum Onkologii
    • West Pomeranian Voivodeship
      • Szczecin, West Pomeranian Voivodeship, Polen
        • Specjalistyczny Szpital im. Alfreda Sokolowskiego
      • Chelaybinsk, Rusland, 454087
        • State Budget Institution of Healthcare "Chelyabinsk Regional Clinical Oncology Dispensary"
      • Ivanovo, Rusland
        • Ivanovo Regional Oncology Centre
      • Moscow, Rusland
        • Cancer Research Center n.a. N.N. Blokhin
      • Nizhny Novgorod, Rusland, 603081
        • GUZ of Nizhegorodskiy region, Nizhnij Novgorod City Oncology Dispensary
      • Saint Petersburg, Rusland, 194044
        • State Educational Institution "S.M. Kirov Military Medical Academy of Ministry of Defense of Russia"
      • Saint Petersburg, Rusland
        • Saint-Petersburg State Medical University n. a. I. P. Pavlov
      • Yaroslavl, Rusland, 150040
        • State healthcare institution of Yaroslavl region "Regional Clinical Oncologic Hospital"
    • Bashkortostan Republic
      • Ufa, Bashkortostan Republic, Rusland, 450054
        • Republic Clinical Oncology Dispensary of the Ministry of Healthcare of Republic of Bashkortostan
    • Moscow
      • Moscow Region, Moscow, Rusland, 143423
        • City Oncology Hospital # 62
    • Primorskiy (Maritime) Kray
      • Arkhangelsk, Primorskiy (Maritime) Kray, Rusland, 163045
        • State Institution of Healthcare "Arkhangelsk Regional Clinical Oncology Dispensary"
    • Tatarstan Republic
      • Kazan', Tatarstan Republic, Rusland
        • Republican Clinical Oncologic Dispensary of Ministry of health of Republic Tatarstan
      • Taichung, Taiwan, 40447
        • China Medical University Hospital
    • Hajdú-Bihar
      • Debrecen, Hajdú-Bihar, Ungarn
        • Debreceni Egyetem Orvos és Egészségtudományi Centrum
    • Heves County
      • Mátraháza, Heves County, Ungarn
        • Mátrai Gyógyintézet

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Documented extensive-stage small cell lung cancer.
  • Patient has received no prior chemotherapy, adjuvant therapy, or radiotherapy for lung cancer.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
  • Adequate bone marrow and organ function based on the results of protocol- specified laboratory tests.
  • Male and female patients must agree to use a highly reliable method of birth control during study participation.
  • Able to provide informed consent

Exclusion Criteria:

  • Previously untreated (non-irradiated), symptomatic brain metastases.
  • Known allergy to any of the study drugs or their excipients.
  • Any unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a patient and/or their compliance with the protocol, based on screening tests, physical examination and medical history (as specifically defined in the clinical protocol).
  • Any malignancy other than small cell lung cancer within the last 5 years prior to randomization, with the exception of cervical carcinoma in situ, nonmelanoma skin cancer, or superficial bladder tumors (Ta, Tis, or T1) that have been successfully and curatively treated with no evidence of recurrent or residual disease. (Exception: Subjects with a history of malignancy other than small cell lung cancer may be enrolled after consultation with the medical monitor provided the patient's prognosis is best defined by the extensive-stage small cell lung cancer).
  • Currently pregnant or nursing.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Palifosfamide-tris plus Carboplatin and Etoposide

Drug: palifosfamide-tris in combination with carboplatin and etoposide palifosfamide-tris: 130 mg/m2/day 3 days every 21 days for a max of 6 cycles. carboplatin: AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles. etoposide: 100 mg/m2/day 3 days every 21 days for a max of 6 cycles.

AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles.

130 mg/m2/day 3 days every 21 days for a max of 6 cycles.

100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles.

AUC 5 mg/mL/min 1 day every 21 days for a max of 6 cycles.

Aktiv komparator: Carboplatin plus Etoposide

Drug: carboplatin in combination with etoposide carboplatin: AUC 5mg/mL/min 1 day every 21 days for a maximum of 6 cycles. etoposide: 100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles.

AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles.

100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles.

AUC 5 mg/mL/min 1 day every 21 days for a max of 6 cycles.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Samlet overlevelse (OS)
Tidsramme: Vurderet hver 12. uge for overlevelse indtil 1 år efter afslutning af tilmelding
Vurderet hver 12. uge for overlevelse indtil 1 år efter afslutning af tilmelding

Sekundære resultatmål

Resultatmål
Tidsramme
Progressionsfri overlevelse (PFS)
Tidsramme: Vurderet hver 6. uge i 22 uger, derefter hver 12. uge indtil fremadskridende sygdom, påbegyndelse af alternativ kræftbehandling eller 1 år efter den sidst indrullerede patient (alt efter hvad der er hurtigst)
Vurderet hver 6. uge i 22 uger, derefter hver 12. uge indtil fremadskridende sygdom, påbegyndelse af alternativ kræftbehandling eller 1 år efter den sidst indrullerede patient (alt efter hvad der er hurtigst)
Objektiv responsrate (ORR)
Tidsramme: Vurderet hver 6. uge i 22 uger, derefter hver 12. uge, indtil et delvist eller fuldstændigt svar er bekræftet
Vurderet hver 6. uge i 22 uger, derefter hver 12. uge, indtil et delvist eller fuldstændigt svar er bekræftet
Svarvarighed
Tidsramme: Tid fra datoen for første objektive respons (delvis eller fuldstændig respons), med efterfølgende bekræftelse, indtil datoen for sygdomsprogression eller forekomsten af ​​dødsfald
Tid fra datoen for første objektive respons (delvis eller fuldstændig respons), med efterfølgende bekræftelse, indtil datoen for sygdomsprogression eller forekomsten af ​​dødsfald
Quality of Life (QOL) as Assessed by the EuroQol 5-Dimension 3-Level Questionnaire (EQ-5D-3L) and the European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Module (QLQ-LC13)
Tidsramme: Assessed every 3 weeks for 22 weeks, then every 12 weeks until 1 year following the last patient enrolled
Assessed every 3 weeks for 22 weeks, then every 12 weeks until 1 year following the last patient enrolled
Safety Parameters (Adverse Events and Number of Findings: Physical Examinations, Electrocardiograms [ECGs], Vital Signs, and Clinical Laboratory Results) Using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) 4.03
Tidsramme: 22 weeks
22 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

8. juni 2012

Primær færdiggørelse (Faktiske)

2. december 2014

Studieafslutning (Faktiske)

2. december 2014

Datoer for studieregistrering

Først indsendt

12. marts 2012

Først indsendt, der opfyldte QC-kriterier

13. marts 2012

Først opslået (Anslået)

15. marts 2012

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

1. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

29. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • IPM3002

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .